Mersana Therapeutics Inc
NASDAQ:MRSN 3:59:58 PM EDT
| Market Cap (Intraday) | 364.60M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.55 |
| 50-Day MA | $6.46 |
| 200-Day MA | $10.89 |
Mersana Therapeutics Inc Stock, NASDAQ:MRSN
840 Memorial Drive, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.498.0020
Number of Employees: 110
Description
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.